FCB lands two DTC accounts

Share this article:
FCB was awarded the DTC advertising for Hoffman-LaRoche's two drugs, Pegasys and Copegus, that treat hepatitis C. Annual media spending for upcoming campaigns could exceed $30 million, sources said.
The agency, which is a unit of the Interpublic Group, pitched against three other undisclosed agencies.
Pegasys and Copegus were approved by the FDA two years ago, but this marks the first DTC campaign for both. The FDA has granted a six-month Priority Review Status to the supplemental new biologics license application (sBLA) for the combination therapy of Pegasys in combination with Copegus for the treatment of hepatitis C in patients who are also infected with HIV. Roche submitted this file with the FDA in August 2004.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions